--- title: "China Medical System Holdings Limited (8A8.SG)" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/8A8.SG.md" symbol: "8A8.SG" name: "China Medical System Holdings Limited" industry: "Pharmaceuticals" datetime: "2026-05-21T19:26:56.856Z" locales: - [en](https://longbridge.com/en/quote/8A8.SG.md) - [zh-CN](https://longbridge.com/zh-CN/quote/8A8.SG.md) - [zh-HK](https://longbridge.com/zh-HK/quote/8A8.SG.md) --- # China Medical System Holdings Limited (8A8.SG) ## Company Overview China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China. The company offers cardio-cerebrovascular products include VELPHORO, a sucroferric oxyhydroxide chewable tablets and diazepam nasal spray for seizure clusters; XinHuoSu, a recombinant human brain natriuretic peptide for acute heart failure; Plendil, a felodipine sustained release tablets for hypertension; and Deanxit, a flupentixol and melitracen tablets for mild-to-moderate depression. It also provides gastroenterology products, such as METOJECT, a methotrexate injection to treat severe recalcitrant disabling psoriasis and rheumatoid arthritis; LUMEBLUE, a methylthioninium chloride enteric-coated sustained-release tablets for colorectal lesion visualization; Salofalk for ulcerative colitis and Crohn’s disease; Bioflor, a saccharomyces boulardii sachets for diarrhea; Combizym and Cidine for digestive enzymes; and Ursofalk, a ursodeoxycholic acid capsules to treat cholesterol gallstones. In addition, the company offers dermatology products, including ILUMETRI, a tildrakizumab injection for the treatment of plaque psoriasis; Aethoxysklerol, a polidocanol injection for sclerotherapy of various varicose veins; Hirudoid, a mucopolysaccharide polysulfate cream to treat blunt traumata; skin heling soothing product; and Hirudoid for acne-prone skin care, prevention, and enhancement of acne. | Item | Detail | |------|--------| | Industry | Pharmaceuticals | | Exchange | SG Market | | Website | [web.cms.net.cn/zh/home/](https://web.cms.net.cn/zh/home/) | ## Key Drivers > *AI-analyzed key factors driving this stock's performance* ## Longbridge Financial Score™: B > *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge* > Updated: 2026-05-21T04:30:16.000Z **Overall: B (0.36)** **Industry**: Pharmaceuticals | Metric | Value | |--------|-------| | Industry Ranking | 1 / 6 | | Industry Median | C | | Industry Average | C | - **Style**: Value - Stocks where the company's main business is in a mature stage. - **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock. **Multi Score**: B #### Style Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | 7.59% | | | Net Profit YoY | -10.05% | | | P/B Ratio | 1.38 | | | Dividend Ratio | 2.90% | | #### Size Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 4408346054.43 | | | Revenue | 1487784116.31 | | #### Multi Score Score: B | Indicator | Value | Rating | |-----------|-------|--------| | ROE | 8.83% | B | | Profit Margin | 18.13% | A | | Gross Margin | 71.50% | A | | Revenue YoY | 7.59% | C | | Net Profit YoY | -10.05% | D | | Total Assets YoY | 4.78% | C | | Net Assets YoY | 5.34% | C | | Cash Flow Margin | 50.94% | C | | OCF YoY | 7.59% | C | | Turnover | 0.44 | C | | Gearing Ratio | 8.63% | A | ```chart-data:radar { "title": "Longbridge Financial Score - China Medical System Holdings Limited", "chart_type": "radar", "dimensions": [ { "name": "Style Score", "grade": "", "indicators": [ { "name": "Revenue YoY", "value": "7.59%", "rating": "" }, { "name": "Net Profit YoY", "value": "-10.05%", "rating": "" }, { "name": "P/B Ratio", "value": "1.38", "rating": "" }, { "name": "Dividend Ratio", "value": "2.90%", "rating": "" } ] }, { "name": "Size Score", "grade": "", "indicators": [ { "name": "Market Cap", "value": "4408346054.43", "rating": "" }, { "name": "Revenue", "value": "1487784116.31", "rating": "" } ] }, { "name": "Multi Score", "grade": "B", "indicators": [ { "name": "ROE", "value": "8.83%", "rating": "B" }, { "name": "Profit Margin", "value": "18.13%", "rating": "A" }, { "name": "Gross Margin", "value": "71.50%", "rating": "A" }, { "name": "Revenue YoY", "value": "7.59%", "rating": "C" }, { "name": "Net Profit YoY", "value": "-10.05%", "rating": "D" }, { "name": "Total Assets YoY", "value": "4.78%", "rating": "C" }, { "name": "Net Assets YoY", "value": "5.34%", "rating": "C" }, { "name": "Cash Flow Margin", "value": "50.94%", "rating": "C" }, { "name": "OCF YoY", "value": "7.59%", "rating": "C" }, { "name": "Turnover", "value": "0.44", "rating": "C" }, { "name": "Gearing Ratio", "value": "8.63%", "rating": "A" } ] } ] } ``` ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | 16.16 | 3/6 | 19.46 | 18.34 | 17.62 | | PB | 1.37 | 3/6 | 1.90 | 1.79 | 1.71 | | PS (TTM) | 2.93 | 3/6 | 4.00 | 3.80 | 3.64 | | Dividend Yield | 2.93% | 4/6 | 2.22% | 1.24% | 1.17% | ## Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | | --- | --- | --- | --- | --- | --- | --- | --- | | 01 | CMS (8A8.SG) | B | C | C | A | C | B | | 02 | Haw Par (H02.SG) | B | D | E | A | D | C | | 03 | TJ DaRenTang USD (T14.SG) | A | D | C | B | D | C | | 04 | IX Biopharma (42C.SG) | D | C | C | B | C | C | | 05 | Hyphens Pharma (1J5.SG) | B | D | A | C | C | C | ## References - [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/8A8.SG/overview.md) - [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/8A8.SG/norm.md) - [Related News](https://longbridge.com/en/quote/8A8.SG/news.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**